BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (March 2015)

23 slides from BioSpecifics Technologies's investor presentation, Mar 4, 2015

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development DUPUYTRE! & commercialization of _ INJECTABLE COLLAGENASE ae BioSpecifics March 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company

    BioSpecifics is a profitable, commercial-stage biopharma company receiving increasing revenues for sales of collagenase clostridium histolyticum or CCH (XIAFLEX®) by partner Auxilium. Future revenue growth opportunities emerging from commitment to clinical development of new indications for CCH.

  4. Slide 4: Vast Potential of CCH

    Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive results in 12 indications: Dupuytren’s contracture’ — Frozen shoulder Scarred tendons Peyronie’s disease * sy

  5. Slide 5: Auxilium Acquired by Endo International

    Auxilium Acquired by Endo International As of January 29, 2015, Auxilium Pharmaceuticals, Inc. (Auxilium) is now a wholly-owned subsidiary of Endo International plc (Endo). » Cash and stock transaction for approximately $2.6B* Endo stock value appreciated ~20% from date of transaction announcement t

  6. Slide 6: Marketed Indications for XIAFLEX

    Marketed Indications for XIAFLEX Impressive Revenue Growth Revenue-Generating Products Dupuytren’s Approved in the U.S., EU, Canada & Australia; under Contracture review in Japan Peyronie’s Disease Approved in the U.S. and EU (as of January 2015)

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture First and Only FDA- and EMA-Approved Nonsurgical Treatment Definition sBLA Approved Label Expansion in October 2014 Based on Phase 3b MULTICORD Study Potential for Commercial Expansion Source: Auxilium Pharmaceuticals, Inc. Collagen cord in the hand causing one or

  8. Slide 8: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Sobi Received Approval for XIAPEX in EU First and Only FDA- and EMA-Approved Nonsurgical Treatment Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Definition & Associated with pain with erection, penile shortenin

  9. Slide 9: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Pindeton| Prec | Paset | Phase | Pe | rate | oe Top-line data in 1Q15 Cellulite Planning of Phase 2b trial * Human Complete enrollment in Phase 2 in 1H15 Lipoma *Uterine Encouraging Fibroids data reported aiTiNe Auxilium to determine

  10. Slide 10: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Potential to be Only FDA Approved Nonsurgical Therapy Market Opportunity Source: Auxiiu

  11. Slide 11: Phase 2b Study of CCH in Frozen Shoulder

    Phase 2b Study of CCH in Frozen Shoulder Top-line Data Anticipated in 1Q15 Double-blind, placebo-controlled study evaluating safety and Phase 2b Study efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Initiated based on statistically significant Phase 2a results " Patients ran

  12. Slide 12: Statistically Significant CCH Dose Response in Phase 2a Study

    Statistically Significant CCH Dose Response in Phase 2a Study ~60 1 1 Statistically significant improvements in a 7 go: | ET both the 0.58 mg(ImL) and 0.58 50: to Exercise Coho: © -srouderabauction mg(2mL) cohorts over baseline scores External Rotation vs. the exercise-only group: fo a) INEMaL ROAD

  13. Slide 13: CCH for Cellulite

    CCH for Cellulite Positive Phase 2a Top-line Results Reported in 3Q14 Definition Significant Market Opportunity as First Nonsurgical Therapy Positive Top-line Results Reported from Phase 2a Study in3Q14 Source: Auxilium Pharmaceuticals, Inc. Skin dimpling as a result of collagen fibrous septae, occu

  14. Slide 14: CCH for Cellulite

    CCH for Cellulite Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatment Well-tolerated by all dose groups with m

  15. Slide 15: CCH for Human Lipomas

    CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Definition Potential to be Only Approved Nonsurgical Therapy U.S. Market Opportunity Enrollment of Phase 2 Opt-in Clinical Study to be Completed in 1H15 Encapsulated deposits of benign fatty tumors; detected as bulges under the skin

  16. Slide 16: Positive Phase 2 Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of comme

  17. Slide 17: CCH for Lipomas in Canines

    CCH for Lipomas in Canines Auxilium to Manage Development Program Key Complications Potential to be Only Approved Nonsurgical Therapy $500K Opt-In Payment to BioSpecifics Opt-In Based on Chien-804 Results Lipomas can cause seriously restrict motion in older dogs Surgery can be risky due to the use o

  18. Slide 18: CCH for Uterine Fibroids

    CCH for Uterine Fibroids New Study Results Reported in October 2014 Eee Definition & Pain, decreased fertility, see Key Ci licati miscarriage, heavy menstrual — 00 ey Complications bleeding and frequent urination H ae i= ss00 [ie Potential to be Primary indication for 000 025 050 100 200 4 ; Collage

  19. Slide 19: Auxilium Partnership for Development and Commercialization of CCH

    Auxilium Partnership for Development and Commercialization of CCH >$48M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Auxilium Opt-In Rights Milestone Payments from Auxilium Partnerships $48M received in licensing, sublicensing, milestone, COGS, and royalty payments as of

  20. Slide 20: Corporate Highlights

    Corporate Highlights Projected Revenue Growth from Higher Royalties Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong IP portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protectio

  21. Slide 21: Consistently Profitable Annually

    Consistently Profitable Annually 3Q14 Financial Highlights For the quarter For the year ended ended 09/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments S 17,500,003 $ 12,591,825 Income Statement Revenues S 4,012,787 S 14,467,240 Other income 8,121 26,202 Costs and

  22. Slide 22: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Upcoming Milestones *Human Q Complete enrollment in Phase 2 placebo-controlled opt-in trial in 1H15 Lipomas *Uterine O Refining development plan Fibroids . a Dupuytren’s ) Decision on approval by PMDA in Japan expected by mid-2015 Contracture Frozen i A Shoulder O Ann

  23. Slide 23: Innovators in the development & commercialization of injectable collagenase

    - — a —s é ya? Innovators in the development DUPUYTRE! & commercialization of _ INJECTABLE ~«.— COLLAGENASE —_——— : BioSpecifics March 2015

Biospecifics Technologies — Investor Presentation (March 2015) on 6ix